PIK3CA and breast carcinoma: In summary, our findings demonstrate that the simultaneous suppression of the combination of the PI3K/mTOR inhibitor BEZ235 and the pan-HDAC inhibitor TSA is more effective than single agent in inhibiting the viability of breast cancer cells in vitro and tumour progression in vivo.